Divisions of Plastic Surgery and Surgical Oncology, University of Calgary, Calgary, Alberta, Canada; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
J Surg Oncol. 2014 Mar;109(4):327-31. doi: 10.1002/jso.23556. Epub 2014 Jan 22.
Intra-lesional interleukin-2 (IL-2) is effective in treating in transit melanoma metastases. Results from multiple studies were examined to evaluate the efficacy of IL-2 for in transit disease. In the published literature, complete response ranged from 0% to 69% per patient, and 41% to 96% per lesion, with excellent tolerability. Combining the results of six studies show complete response in 50% of patients and 78% of lesions. Intra-lesional IL-2 should be considered early in the course of treatment for in transit disease, ahead of other, more toxic therapies.
病灶内注射白细胞介素-2（IL-2）对治疗转移性黑色素瘤有效果。本研究分析了多项研究结果，以评估 IL-2 治疗转移疾病的疗效。文献报道，病灶内注射 IL-2 治疗患者的完全缓解率为 0%至 69%，完全缓解率为 41%至 96%，且耐受性良好。6 项研究结果综合分析显示，病灶内注射 IL-2 治疗患者的完全缓解率为 50%，完全缓解率为 78%。对于转移性疾病，应尽早考虑病灶内注射 IL-2，而不是采用其他毒性更大的治疗方法。
